Athos expands its autonomous AI analytics platform to accelerate the development of precision therapies for patients with immune-mediated diseases and cancer.
Vultr, a large-scale privately held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has selected Vultr Cloud GPUs to train, tune, and perform inference on its AI models. Powered by NVIDIA HGX H100 systems and running on Dell Technologies PowerEdge XE9680 servers, Vultr provides the security and confidentiality required for Athos' intellectual property, omics* data, and proprietary AI algorithms.
Led by one of the founders of Kite Pharma, Athos is the medicinal chemist behind two multi-billion dollar FDA approved drugs and the discoverer of the miR-124 drug target currently in Phase III IBD trials. Athos is pioneering artificial intelligence (AI) and machine learning (ML) based precision small molecule therapeutics for immune mediated diseases and cancer patients. Currently, Athos aims to unravel the complexities of autoimmune and cancer biology by assessing disease at the molecular level. To achieve this, the company has partnered with leading global hospitals across the US, including Cleveland Clinic, Lahey Hospital & Medical Center, and Ioannina University School of Medicine, to perform multi-omics analysis of over 25,000 patients. Athos has also partnered with California Institute of Technology to perform spectroscopy-based proteomics using cultured cells and biopsies of archived and de-identified patient samples.
To accelerate the development of precision medicines, Athos needed a cost-effective, flexible, and high-performance cloud infrastructure that could rapidly scale its omics data and proprietary AI algorithms without compromising security and confidentiality. Training algorithms with public cloud providers was cost-prohibitive and offered limited engineering support. That's why Athos selected Vultr to train its AI algorithms with reliable, secure, and compliant access to NVIDIA GPUs. With Vultr, Athos' fully autonomous AI analytics platform, including the Athos data lake and state-of-the-art integrated deep learning engine, can seamlessly train large datasets while ensuring all AI training data is bound by local data sovereignty, data residency, and privacy regulations.
“Empowering the next generation of innovators is core to our mission to democratize access to high-performance cloud computing,” said JJ Kardwell, CEO of Vultr's parent company Constant. “And for companies like Athos, which operate in highly regulated industries, security and compliance are top priorities for maintaining operational excellence. We're proud to work with Athos to provide the scalable, high-performance, safe and secure infrastructure that underpins their platform as they continue to scale and deliver life-changing therapies to patients around the world.”
“Breakthrough medical research requires dynamic, reliable computing power,” said Travis Vigil, senior vice president, ISG product management, Dell Technologies. “Running Vultr's cloud platform on Dell PowerEdge XE9680 servers helps Athos run AI workloads securely at scale to develop precision small molecule therapeutics that can improve countless lives.”
By choosing the Vultr AI cloud platform, Athos can easily train, tune, monitor, and manage various AI algorithms and also enjoys the following benefits:
- Scalable and agile cloud GPU resources – Adapt to growing data needs, eliminate the complexity of GPU management, and reduce the long-term costs of AI infrastructure.
- User-friendly interface – It enables seamless interaction with Vultr's compute resources, accelerating algorithm training and does not require deep expertise in GPU configuration and provisioning.
- Ongoing monitoring and management – Optimize resources, increase hardware utility, and improve efficiency.
- Unparalleled security, confidentiality and data sovereignty – Address diverse global risk and compliance needs critical to Athos omics data and proprietary AI algorithms.
- 24/7 Support – We provide around-the-clock disaster recovery, engineering support, and maintenance that are essential to recover checkpoints of Athos’ omics data and AI algorithms in the event of hardware or software failure.
“Athos is on a mission to deliver new precision therapies to patients with autoimmune diseases and cancer,” said Dimitrios Iliopoulos, PhD, MBA, president and CEO of Athos. “We are pleased to work with Vultr and Dell to help our AI compute team achieve this goal by leveraging the power of NVIDIA H100 GPUs at scale. With Vultr's support, we have been able to minimize downtime and maximize productivity across our business.”
*Omics refers to the field of study in biology that focuses on the roles, relationships, and actions of different types of molecules that make up an organism's cells. Omics includes various sub-disciplines that focus on different aspects of biological function, including genomics, metabolomics, proteomics, transcriptomics, epigenomics, lipidomics, glycomics, and phenomics.
Sign up for the free insideBIGDATA newsletter.
Join us on Twitter: https://twitter.com/InsideBigData1
Join us on LinkedIn: https://www.linkedin.com/company/insidebigdata/
Join us on Facebook: https://www.facebook.com/insideBIGDATANOW
